Drawbridge's POC HbA1c test cleared for Europe

By LabPulse.com staff writers

February 4, 2020 -- The OneDraw single-use, point-of-care (POC) test for hemoglobin A1c (HbA1c) has the CE Mark for sale in European markets, according to its developer, Drawbridge Health, a private company founded by General Electric.

The product is intended for long-term monitoring of blood sugar in adults with diabetes, noted Drawbridge, which is based in Menlo Park, CA. Using the device, medical professionals can collect blood via light vacuum suction as an alternative to methods that involve hypodermic needles or finger sticks. Specimens are taken from the device through a removable cartridge and mailed to a certified lab for analysis.

Drawbridge will introduce the product in "select countries" in Europe this year, the company said in a statement. The OneDraw test was cleared by the U.S. Food and Drug Administration in August 2019.

Barbershop POC blood tests pick up undiagnosed diabetes
Barbershops are good places for on-the-spot testing of black men for hemoglobin A1c, according to a study published January 27 in JAMA Internal Medicine....
Self-testing helps drive demand for bustling HbA1c market
Bruce Carlson, publisher of Kalorama Information, explores factors driving the demand for hemoglobin A1c (HbA1c) testing in people with diabetes, including...
Point-of-care testing tackles diabetes risk in Texas
One of the key advantages of point-of-care (POC) testing is the ability to offer test results within a matter of minutes, instead of several hours or...
Blood sugar test from GE's Drawbridge clears FDA
Drawbridge Health, a privately held company founded by GE, announced that its OneDraw single-use point-of-care device for testing hemoglobin A1c in people...

Copyright © 2020 LabPulse.com

Last Updated np 2/4/2020 1:35:00 PM

Register below for our weekly Letter from the Editor to receive the latest Clinical Lab news and insights.